SCHEMBL1994625

SCHEMBL1994625

CN1C(=O)c2ccccc2[C@]12CC[C@@H](C(=O)O)CC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.47
KDM4E B2RXH2 1/20 0.41
HTR2A P28223 2/20 0.40
HTR2C P28335 2/20 0.40
HRH1 P35367 2/20 0.40
HTR2B P41595 2/20 0.40
EBP Q15125 1/20 0.39
DHCR7 Q9UBM7 1/20 0.39
KMT2A Q03164 2/20 0.39
APAF1 O14727 1/20 0.39
NSD2 O96028 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
CASP3 P42574 1/20 0.39
RECQL P46063 1/20 0.39
GALK1 P51570 1/20 0.39
HKDC1 Q2TB90 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1994624 1.00 HRH3 (0.47) HRH3KDM4EHTR2AHTR2CHRH1
SCHEMBL1999498 1.00 HRH3 (0.47) HRH3KDM4EHTR2AHTR2CHRH1
SCHEMBL30372076 0.82 HRH3 (0.51) HRH3KDM4EEBPDHCR7KMT2A
SCHEMBL4367103 0.79 HRH3 (0.60) HRH3KMT2APOLBMAPTMEN1
SCHEMBL4367104 0.79 HRH3 (0.60) HRH3KMT2APOLBMAPTMEN1
SCHEMBL30620824 0.79 HRH3 (0.52) HRH3KDM4EEBPDHCR7KMT2A
SCHEMBL30564277 0.79 HRH3 (0.52) HRH3KDM4EEBPDHCR7KMT2A
SCHEMBL8843237 0.76 HRH3 (0.53) HRH3KDM4EHTR2AHTR2CHTR2B
SCHEMBL2000776 0.75 HRH3 (0.72) HRH3
SCHEMBL2001915 0.75 HRH3 (0.72) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960402-B2 Trans-5'-(2-fluoroethoxy)-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-isobenzofuran]-4-carboxamide hydrochloride; histamine H3 receptor antagonist or inverse agonist; metabolic disorders; circulatory diseases; nervous system diseases; psychological disorders; sleep disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-14 US disclosed
EP-1795527-B1 CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMA CO LTD (JP) 2009-04-22 EP disclosed
US-20080171753-A1 Carbamoyl-Substituted Spiro Derivative MSD K.K. (JP) 2008-07-17 US disclosed
EP-1795527-A1 CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171753-A1 Carbamoyl-Substituted Spiro Derivative HRH3, HRH4, HRH2 HRH3 1/4885KDM4E 607/4885HTR2A 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.